Summary
Global Markets Direct’s, ‘Helicobacter pylori Infections - Pipeline Review, H2 2016’, provides an overview of the Helicobacter pylori Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
- The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
- The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Daewoong Pharmaceutical Co., Ltd.
Debiopharm International SA
EpiVax, Inc.
Frost Biologic, Inc.
ImevaX GmbH
ImmunoBiology Limited
Recce Pty Ltd
RedHill Biopharma Ltd.
Sequella, Inc.
Sigmoid Pharma Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Helicobacter pylori Infections Overview 7
Therapeutics Development 8
Pipeline Products for Helicobacter pylori Infections - Overview 8
Pipeline Products for Helicobacter pylori Infections - Comparative Analysis 9
Helicobacter pylori Infections - Therapeutics under Development by Companies 10
Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes 11
Helicobacter pylori Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Helicobacter pylori Infections - Products under Development by Companies 15
Helicobacter pylori Infections - Products under Investigation by Universities/Institutes 16
Helicobacter pylori Infections - Companies Involved in Therapeutics Development 17
Daewoong Pharmaceutical Co., Ltd. 17
Debiopharm International SA 18
EpiVax, Inc. 19
Frost Biologic, Inc. 20
ImevaX GmbH 21
ImmunoBiology Limited 22
Recce Pty Ltd 23
RedHill Biopharma Ltd. 24
Sequella, Inc. 25
Sigmoid Pharma Limited 26
Helicobacter pylori Infections - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 34
Drug Profiles 36
(amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Debio-1453 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DWJ-1325 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
FROST-900 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Helicobacter pylori vaccine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Helicobacter pylori vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Helicobacter pylori vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Helicobacter pylori vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
HPi-1 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
IMX-101 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
RECCE-327 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules for Helicobacter Pylori Infections - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
SQ-109 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Helicobacter pylori Infections - Dormant Projects 57
Helicobacter pylori Infections - Product Development Milestones 58
Featured News & Press Releases 58
Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection 58
Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection 59
Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105 60
Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study’s Positive Results 61
Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection 62
Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection 63
Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection 64
Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study 64
Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results 65
May 18, 2015: RedHill Biopharma’s Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market 67
May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study 68
Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection 69
Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment 70
Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105 71
Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75
List of Tables
Number of Products under Development for Helicobacter pylori Infections, H2 2016 8
Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 17
Helicobacter pylori Infections - Pipeline by Debiopharm International SA , H2 2016 18
Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H2 2016 19
Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H2 2016 20
Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H2 2016 21
Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H2 2016 22
Helicobacter pylori Infections - Pipeline by Recce Pty Ltd, H2 2016 23
Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2016 24
Helicobacter pylori Infections - Pipeline by Sequella, Inc., H2 2016 25
Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Helicobacter pylori Infections - Dormant Projects, H2 2016 57
List of Figures
Number of Products under Development for Helicobacter pylori Infections, H2 2016 8
Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Targets, H2 2016 29
Number of Products by Stage and Targets, H2 2016 29
Number of Products by Mechanism of Actions, H2 2016 31
Number of Products by Stage and Mechanism of Actions, H2 2016 31
Number of Products by Stage and Routes of Administration, H2 2016 33
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34
